CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Buy” by Analysts

Shares of CG Oncology, Inc. (NASDAQ:CGON) have been assigned an average rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $64.17.

Several equities analysts recently commented on the stock. Bank of America started coverage on shares of CG Oncology in a report on Friday, June 28th. They set a “buy” rating and a $65.00 target price on the stock. Roth Capital upgraded CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of CG Oncology in a report on Tuesday. Finally, Roth Mkm started coverage on CG Oncology in a research note on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price target on the stock.

Insider Buying and Selling

In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the transaction, the director now owns 586,982 shares in the company, valued at approximately $20,755,683.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Investors Weigh In On CG Oncology

Several hedge funds have recently added to or reduced their stakes in the stock. Decheng Capital LLC bought a new position in shares of CG Oncology during the first quarter valued at $239,642,000. Vanguard Group Inc. purchased a new stake in CG Oncology during the 1st quarter valued at about $97,678,000. BVF Inc. IL bought a new stake in CG Oncology during the 1st quarter valued at about $82,716,000. Yu Fan purchased a new position in CG Oncology in the second quarter worth about $49,828,000. Finally, Janus Henderson Group PLC bought a new position in shares of CG Oncology in the first quarter worth approximately $66,757,000. 26.56% of the stock is owned by institutional investors.

CG Oncology Trading Down 0.3 %

Shares of NASDAQ:CGON opened at $39.00 on Friday. CG Oncology has a 52-week low of $25.77 and a 52-week high of $50.23. The firm has a fifty day moving average of $35.29 and a 200 day moving average of $35.37.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.14. The firm had revenue of $0.11 million for the quarter. As a group, equities analysts anticipate that CG Oncology will post -1.47 earnings per share for the current fiscal year.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.